You can buy or sell AMPE and other stocks, options, ETFs, and crypto commission-free!
Ampio Pharmaceuticals, Inc, also called Ampio Pharmaceuticals, is a biopharmaceutical company, that engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease. Read More The company was founded by David Bar-Or in April 2010 and is headquartered in Englewood, CO.
52 Week High
52 Week Low
Seeking AlphaApr 29
Ampio not quite there with confirmatory study of Ampion; shares down 5% premarket
Nano cap Ampio Pharmaceuticals (NYSEMKT:AMPE) slips 5% premarket on light volume in reaction to its announcement that the FDA does not want it to start its confirmatory trial of Ampion in patients with knee osteoarthritis without the agency's agreement on the trial design.
Yahoo FinanceApr 29
Ampio Pharmaceuticals Provides Regulatory Update
ENGLEWOOD, Colo., April 29, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has received comments from the U.S. Food and Drug Administration (FDA) regarding their Special Protocol Assessment (SPA). The FDA recommended the Company not start their confirmatory trial without obtaining FDA concurrence on the trial design. The Company agreed with the comments they received from the FDA and immediately sent a revised SPA to the FDA for review. Ampio Pharmaceuticals Logo....
Expected May 13, After Hours